Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Up 90.7% in August

Estrella Immunopharma, Inc. (NASDAQ:ESLA) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 117,132 shares, a growth of 90.7% from the August 15th total of 61,410 shares. Based on an average daily volume of 34,578 shares, the days-to-cover ratio is currently 3.4 days. Approximately 0.3% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings lowered shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Estrella Immunopharma presently has an average rating of “Hold” and a consensus price target of $8.00.

Institutional Trading of Estrella Immunopharma

An institutional investor recently bought a new position in Estrella Immunopharma stock. BlackRock Inc. acquired a new stake in shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 52,033 shares of the company’s stock, valued at approximately $54,000. BlackRock Inc. owned 0.12% of Estrella Immunopharma at the end of the most recent quarter. 0.35% of the stock is currently owned by institutional investors.

Estrella Immunopharma Stock Down 13.9%

NASDAQ ESLA traded down $0.09 during trading hours on Thursday, reaching $0.55. 144,678 shares of the company were exchanged, compared to its average volume of 100,645. The stock has a market capitalization of $23.97 million, a P/E ratio of -2.31 and a beta of 0.88. The business’s 50 day simple moving average is $0.73 and its 200-day simple moving average is $1.05. Estrella Immunopharma has a 1 year low of $0.51 and a 1 year high of $3.15.

Estrella Immunopharma (NASDAQ:ESLA) last released its earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. As a group, sell-side analysts anticipate that Estrella Immunopharma will post -0.25 earnings per share for the current year.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.